CN117396227A - siRNA递送载体 - Google Patents

siRNA递送载体 Download PDF

Info

Publication number
CN117396227A
CN117396227A CN202280036975.2A CN202280036975A CN117396227A CN 117396227 A CN117396227 A CN 117396227A CN 202280036975 A CN202280036975 A CN 202280036975A CN 117396227 A CN117396227 A CN 117396227A
Authority
CN
China
Prior art keywords
negatively charged
compound
complex
substituted
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280036975.2A
Other languages
English (en)
Chinese (zh)
Inventor
S·科塔姆拉朱
S·R·巴图拉
A·谢赫
P·K·尼利
P·斯拉维亚
R·班纳吉
R·森纳缇
S·加贾拉克什米
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Council of Scientific and Industrial Research CSIR
Original Assignee
Council of Scientific and Industrial Research CSIR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council of Scientific and Industrial Research CSIR filed Critical Council of Scientific and Industrial Research CSIR
Publication of CN117396227A publication Critical patent/CN117396227A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Medicinal Preparation (AREA)
CN202280036975.2A 2021-06-04 2022-06-03 siRNA递送载体 Pending CN117396227A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202111024926 2021-06-04
IN202111024926 2021-06-04
PCT/IB2022/055214 WO2022254405A1 (en) 2021-06-04 2022-06-03 siRNA DELIVERY VECTOR

Publications (1)

Publication Number Publication Date
CN117396227A true CN117396227A (zh) 2024-01-12

Family

ID=82558096

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280036975.2A Pending CN117396227A (zh) 2021-06-04 2022-06-03 siRNA递送载体

Country Status (8)

Country Link
US (1) US20240277851A1 (https=)
EP (1) EP4346902A1 (https=)
JP (1) JP2024521209A (https=)
CN (1) CN117396227A (https=)
AU (1) AU2022287326A1 (https=)
BR (1) BR112023025242A2 (https=)
CA (1) CA3220535A1 (https=)
WO (1) WO2022254405A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120617243A (zh) * 2024-11-15 2025-09-12 江苏省肿瘤医院 瑞香素作为抑制剂在制备治疗三阴性乳腺癌的药物中的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116159145B (zh) * 2023-01-31 2025-04-22 四川大学 含七叶皂苷和/或其盐化合物的转染复合物在促转染的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2540234B (en) * 2015-02-19 2020-12-02 Council Scient Ind Res An antioxidant compound having anti atherosclerotic effect and preparation thereof
US11213960B2 (en) 2018-09-17 2022-01-04 John AMBIELLI Multi-tool and storage device
AR127082A1 (es) * 2019-11-22 2023-12-20 Council Scient Ind Res Compuestos antiinflamatorios para el tratamiento de trastornos cutáneos

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120617243A (zh) * 2024-11-15 2025-09-12 江苏省肿瘤医院 瑞香素作为抑制剂在制备治疗三阴性乳腺癌的药物中的应用

Also Published As

Publication number Publication date
CA3220535A1 (en) 2022-12-08
US20240277851A1 (en) 2024-08-22
WO2022254405A1 (en) 2022-12-08
AU2022287326A1 (en) 2023-11-30
JP2024521209A (ja) 2024-05-28
EP4346902A1 (en) 2024-04-10
BR112023025242A2 (pt) 2024-02-20

Similar Documents

Publication Publication Date Title
US12233132B2 (en) Polyoxazoline-lipid conjugates and lipid nanoparticles and pharmaceutical compositions including same
US10188738B2 (en) Formulations useful in the treatment of proliferative diseases affecting the respiratory tract
KR20150100706A (ko) 입자 내에 캡슐화된 표적화된 콘쥬게이트 및 이의 제형
Chen et al. Novel glycyrrhetinic acid conjugated pH-sensitive liposomes for the delivery of doxorubicin and its antitumor activities
Markowicz-Piasecka et al. Dendrimers in drug delivery
CN117396227A (zh) siRNA递送载体
US20070208088A1 (en) Pqs: a new hydrotrope for solubilizing lipophilic compounds in water
CN117777089B (zh) 脂质化合物和脂质纳米颗粒组合物
Yuan et al. Tumor permeable self-delivery nanodrug targeting mitochondria for enhanced chemotherapy
CN115337267A (zh) 一种基于脂质体纳米囊泡的酸响应型药物递送平台的制备方法及其应用
CN119528925B (zh) 喜树碱类前药及其载药脂质体和应用
CN120359207A (zh) 一种阳离子脂质材料的制备及应用
JP2010526839A (ja) ポリメラーゼ阻害剤、及び腫瘍の治療のためのそれらの使用
CN120483890B (zh) 多叔胺多尾链可电离阳离子脂质、包含其的组合物及用途
US20250269044A1 (en) Psma-targeted dendrimer nanoplatform for cancer detection and therapy
Li et al. A redox-responsive cationic liposome for PTX lung-specific delivery and pulmonary carcinoma therapy
CN115089720A (zh) 一种肿瘤治疗药物组合
CN119591513A (zh) 局部递送药物的材料及其应用
KR20240111723A (ko) 헤파린이 결합된 표적 항암 치료용 화합물 및 이의 나노입자
Wan Tunable Immunostimulatory Nanocarrier For Improving Cancer Immunochemotherapy
CN119490447A (zh) 药物递送材料及其应用
HK40103124A (zh) 聚恶唑啉-脂质缀合物及包含其的脂质纳米颗粒和药物组合物
EP4727599A2 (en) Poly(oxazoline) conjugates with pendant cationic groups and lipid nanoparticles and polyplexes including same
AU2002342304B2 (en) Agent for improving tissue penetration
CN119033948A (zh) 一种多臂聚乙二醇药物偶联物及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination